Marlborough medical device manufacturer Boston Scientific announced on Friday it was moving forward on a $210-million acquisition of EndoChoice Holdings, Inc. in Georgia.
According to a release from Boston Scientific, the company has officially extended an offer of $8 per share to current EndoChoice shareholders. The board of directors of EndoChoice has unanimously approved the terms of the merger agreement, including the tender offer and has recommended that EndoChoice shareholders tender their shares in the offer. The offer is set to expire on Nov. 4.
